Cue Biopharma (CUE) Short term Debt (2022 - 2026)

Cue Biopharma has disclosed Short term Debt across 5 years of filings, most recently posting $960000.0 for Q2 2026.

• In Q2 2026, Short term Debt fell 60.26% year-over-year to $960000.0; the TTM figure through Jun 2026 stood at $960000.0 (down 60.26% YoY), while the FY2025 annual figure was $689000.0, down 84.1% from the prior year.
• Short term Debt came in at $960000.0 for Q2 2026 at Cue Biopharma, up from $689000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.3 million in Q4 2024 to a low of $689000.0 in Q4 2025.
• Average Short term Debt over 5 years is $2.9 million, with a median of $3.4 million recorded in 2025.
• Year-over-year, Short term Debt surged 300.0% in 2023 and slumped 84.1% in 2025.
• Over 5 years, Short term Debt stood at $2.0 million in 2022, then jumped by 101.88% to $4.0 million in 2023, then advanced by 9.34% to $4.3 million in 2024, then tumbled by 84.1% to $689000.0 in 2025, then soared by 39.33% to $960000.0 in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $960000.0 in Q2 2026, $689000.0 in Q4 2025, and $1.5 million in Q3 2025.